Certa Therapeutics presents new research at ARVO conference in Baltimore
Melbourne, Australia, 03 May 2020: Certa Therapeutics, a biotechnology company focused on improving lives by developing innovative precision treatments for inflammatory and fibrotic diseases, is pleased to announce they will be presenting at the Association for Research in Vision and Ophthalmology (ARVO). Certa will present new research titled ‘Oral delivery of the anti-fibrotic, FT011, achieves […]
Certa Therapeutics attending 38th Annual J.P. Morgan Healthcare Conference in San Francisco to highlight its scientific advancements
Melbourne, Australia, 12 January 2020: Certa Therapeutics, a biotechnology company focused on improving lives by developing innovative precision treatments for inflammatory and fibrotic diseases,is pleased to announce the attendance of the senior management team including Chief Executive Officer, Professor Darren Kelly, at the 38th J.P. Morgan Healthcare Conference. The conference will be held between 13-16 […]
FierceBiotech – In conversation with Darren Kelly, CEO of Certa Therapeutics and OccuRx
At first glance, Darren Kelly doesn’t seem to sleep. He’s the CEO of not one but two fibrosis-related biotechs, an entrepreneur in residence at Brandon Capital, Australia’s largest life sciences-focused VC firm, a director at the Centre for Eye Research Australia and—to top it all off—the associate dean of innovation and enterprise at the University […]
Certa Therapeutics to discuss scientific advancements at BIO conference in Philadelphia
Melbourne, Australia, 03 June 2019: Certa Therapeutics, a biotechnology company focused on improving lives by developing innovative precision treatments for inflammatory and fibrotic diseases. This year’s Biotechnology Innovation Organisation (BIO) International Convention will be attended by Certa Therapeutics and its management team including Chief Executive Officer, Professor Darren Kelly. The BIO convention is set to […]
Certa Therapeutics team to attend 37th Annual J.P. Morgan Healthcare Conference in San Francisco
Melbourne, Australia, 07 January 2019: Certa Therapeutics, a biotechnology company focused on improving lives by developing innovative precision treatments for inflammatory and fibrotic diseases. Certa Therapeutics and its management team including Chief Executive Officer, Professor Darren Kelly, will attend the 27th Annual J.P. Morgan Healthcare Conference. The Certa team will highlight their scientific advancements in […]
Certa Therapeutics Convenes Scientific and Clinical Advisory Board
Melbourne, Australia, November 2018: Certa Therapeutics, a biotechnology company focused on improving lives by developing innovative precision treatments for inflammatory and fibrotic diseases is pleased to announce the appointments of five members to its Scientific and Clinical Advisory Board. The new advisory board will support Certa as it prepares to advance its novel precision medicines […]
Biotechdispatch – BTF backs creation of Certa Therapeutics
The Medical Research Commercialisation Fund (MRCF) and Uniseed have announced a $25 million investment in Certa Therapeutics. The investment is comprised of $22 million from the federal government’s Biotechnology Translation Fund (BTF), the single largest investment by the fund, and $3 million from Uniseed. Certa is initially targeting kidney disease, where scarring leads to kidney […]
University of Melbourne – Certa Therapeutics awarded over $20 million from the Biomedical Translation Fund
Certa Therapeutics, led by CEO and founder Professor Darren Kelly has been awarded $22 million by the Biomedical Translation Fund (BTF), the largest ever investment to date by the Fund in its history, and $3m from Uniseed. Certa Therapeutics aims to develop personalised treatments for kidney disease using genetic technologies, specifically DNA testing to allow […]
Department of Health – $22 Million for a Breakthrough Kidney Disease Treatment
Channel 7 News – Certa Therapeutics
